Q1 2025 Earnings Estimate for IDEAYA Biosciences, Inc. Issued By Wedbush (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Wedbush issued their Q1 2025 EPS estimates for IDEAYA Biosciences in a report released on Tuesday, May 7th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.72) for the quarter. Wedbush currently has a “Outperform” rating and a $52.00 price target on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.26) per share. Wedbush also issued estimates for IDEAYA Biosciences’ Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2028 earnings at $4.10 EPS.

A number of other equities research analysts also recently weighed in on IDYA. JPMorgan Chase & Co. boosted their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Citigroup increased their price target on IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. Royal Bank of Canada lifted their price objective on IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 21st. BTIG Research initiated coverage on IDEAYA Biosciences in a report on Friday, March 8th. They issued a “buy” rating and a $55.00 price objective for the company. Finally, Leerink Partnrs restated an “outperform” rating on shares of IDEAYA Biosciences in a report on Friday, February 23rd. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $47.50.

IDEAYA Biosciences Trading Down 1.9 %

Shares of NASDAQ:IDYA opened at $40.64 on Thursday. The stock has a market capitalization of $3.04 billion, a P/E ratio of -20.22 and a beta of 0.83. IDEAYA Biosciences has a 1-year low of $20.68 and a 1-year high of $47.74. The business has a 50-day moving average price of $42.57 and a two-hundred day moving average price of $38.40.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The firm’s revenue was down 100.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.49) EPS.

Institutional Trading of IDEAYA Biosciences

A number of large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its holdings in shares of IDEAYA Biosciences by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,474 shares of the company’s stock valued at $40,000 after buying an additional 723 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new position in IDEAYA Biosciences in the 1st quarter worth $67,000. AJOVista LLC bought a new position in IDEAYA Biosciences during the 4th quarter worth about $99,000. SG Americas Securities LLC acquired a new stake in shares of IDEAYA Biosciences in the 1st quarter valued at about $101,000. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of IDEAYA Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock valued at $171,000 after purchasing an additional 1,219 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.